

# CITATION REPORT

List of articles citing

**Extension Study of PF-05280586, a Potential Rituximab Biosimilar, Versus Rituximab in Subjects With Active Rheumatoid Arthritis**

**DOI: 10.1002/acr.23586**

**Arthritis Care and Research, 2018, 70, 1598-1606.**

**Source:** <https://exaly.com/paper-pdf/68876127/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
20	Nocebos in rheumatology: emerging concepts and their implications for clinical practice. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 727-740	8.1	47
19	A comprehensive review of rituximab therapy in rheumatoid arthritis patients. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 2977-2994	3.9	29
18	Rituximab biosimilars for lymphoma in Europe. <i>Expert Opinion on Biological Therapy</i> , <b>2019</b> , 19, 1045-1056	5.4	5
17	Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial. <i>Rheumatology</i> , <b>2019</b> , 58, 2193-2202	3.9	22
16	Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 122	5.7	5
15	Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. <i>Clinical Therapeutics</i> , <b>2019</b> , 41, 155-173.e13	3.5	16
14	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , <b>2020</b> , 34, 27-37	7.9	19
13	A Randomized, Double-Blind, Efficacy and Safety Study of PF-05280586 (a Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera) in Subjects with Previously Untreated CD20-Positive, Low-Tumor-Burden Follicular Lymphoma (LTB-FL). <i>BioDrugs</i> , <b>2020</b> , 34, 171-181	7.9	13
12	Rituximab biosimilars in hematologic malignancies: the need for a real-world approach. <i>Future Oncology</i> , <b>2020</b> , 16, 2017-2027	3.6	4
11	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , <b>2020</b> , 108, 734-755	6.1	45
10	Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial. <i>Rheumatology</i> , <b>2021</b> , 60, 256-262	3.9	8
9	A Clinical Review of Biosimilars Approved in Oncology. <i>Annals of Pharmacotherapy</i> , <b>2021</b> , 55, 362-377	2.9	1
8	The results of investigating the efficacy and safety of non-medical switching from the original rituximab to its biosimilar in rheumatoid arthritis patients (AMBIRA study). <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2021</b> , 58, 663-672	0.9	1
7	Update on Maintenance Therapies for ANCA-Associated Vasculitis. <i>Current Treatment Options in Rheumatology</i> , <b>2021</b> , 7, 112	1.3	
6	PROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 57, 1-40	0.9	10
5	Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland). <i>Nauchno-Prakticheskaya Revmatologiya</i> , <b>2019</b> , 57, 46-55	0.9	3
4	Therapeutic applications of biosimilar monoclonal antibodies: Systematic review of the efficacy, safety, and immunogenicity in autoimmune disorders. <i>International Immunopharmacology</i> , <b>2021</b> , 101, 108305	5.8	

3	A Developer's Perspective on Clinical Evidence and Benefits for Rituximab Biosimilar Uptake, with a Focus on CT-P10.. <i>Clinical Drug Investigation</i> , <b>2022</b> , 42, 285	3.2	0
2	Biosimilar Monoclonal Antibodies in Latin America.		
1	Switching Among Biosimilars: A Review of Clinical Evidence. 13,		1